Epidemiology of Ovarian Cancer:New Hypotheses

卵巢癌的流行病学：新假设

• 批准号: 6624239
• 负责人: MARY ANNE ROSSING
• 金额: $ 71.45万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6624239
• 关键词: cancer risk; chemoprevention; clinical research; estrogens; female; hormone related neoplasm /cancer; hormone therapy; human subject; neoplasm /cancer epidemiology; ovary neoplasms; progesterone; women's health

Much of the previous epidemiologic research on ovarian cancer has been conducted within the conceptual with conceptual framework of the ovulation and gonadotropin. However, additional mechanisms must be operative to account for epidemiologic findings regarding this disease. In this study, we will address the hypothesis that progesterone reduces risk of epithelial ovarian cancer. We will examine the relation of exogenous progestins administered as a component of hormone replacement therapy (HRT) with disease risk. We will further assess whether sunlight and dietary sources of vitamin D influence risk. The study will contribute to a better understanding of pathogenic mechanisms of epithelial ovarian cancer, and may provide information leading to new means of reducing the occurrence of this disease. We propose to conduct a population-based, case-control study of epithelial ovarian cancer among women aged 35-74 years residing in thirteen counties of Washington State. Cases will be identified through a population-based cancer registry operating as part of the Surveillance, Epidemiology and End Results Program. Controls will be identified through random digit telephone dialing, and will be selected to be similar in age and area of residence to cases. In-person interviews will be conducted and blood samples will be collected. The findings of this study will have appreciable public health importance. Study of the impact of different HRT regimens, particularly estrogen/progestin combinations, on ovarian cancer risk has been deemed an urgent task for research. Recent calls for reappraisals of the risk/benefit ratio of unopposed estrogen and combined estrogen/progestin HRT highlight the need to understand the relation of these medications with ovarian cancer risk, and to incorporate this knowledge into risk/benefit considerations.

以前的大部分关于卵巢癌的流行病学研究都在概念框架中进行了排卵和促性腺激素的概念框架。但是，其他机制必须操作，以说明有关这种疾病的流行病学发现。在这项研究中，我们将解决以下假设：孕酮降低上皮卵巢癌的风险。我们将研究作为疾病风险的激素替代疗法（HRT）的组成部分的外源孕激素的关系。我们将进一步评估阳光和维生素D的饮食来源是否影响风险。这项研究将有助于更好地了解上皮卵巢癌的致病机制，并可能提供信息，从而导致新的方法减少这种疾病的发生。我们建议在华盛顿州的13个县居住的35-74岁妇女中，对35-74岁的女性进行基于人群的病例对照研究。将通过基于人群的癌症注册表来确定病例，作为监视，流行病学和最终结果计划的一部分。将通过随机数字电话拨号来确定控件，并将选择与案件相似。将进行面对面的访谈，并收集血液样本。这项研究的结果将具有明显的公共健康重要性。研究不同HRT方案的影响，尤其是雌激素/孕激素组合对卵巢癌风险的影响已被认为是研究的紧迫任务。最近需要重新评估无反对雌激素和雌激素/孕激素HRT的风险/利益比率的呼吁，强调了了解这些药物与卵巢癌风险的关系，并将这些知识纳入风险/收益考虑因素中。